NCT05313984View on ClinicalTrials.gov

OptiLUTS Part C: the Development of a Symptom Assessment Tool in Sacral Neuromodulation.

CompletedOBSERVATIONAL
Enrollment

93

Participants

Timeline

Start Date

March 1, 2018

Primary Completion Date

December 1, 2021

Study Completion Date

December 31, 2021

Conditions
Overactive Bladder SyndromeUrinary RetentionDysfunctional VoidingFecal IncontinenceFowler Syndrome
Interventions
DEVICE

Sacral neuromodulation

"Sacral neuromodulation: the 2-staged tined lead procedure. (Interstim II therapy, Medtronic).~Stage I: Placement of a tined-lead electrode. 2 - 4 weeks test phase. Stage II: Placement of an implantable pulse generator."

Trial Locations (1)

9000

Department of Urology, Ghent University Hospital, Ghent

Sponsors

Collaborators (1)

Medtronic
All Listed Sponsors
collaborator

Medtronic

INDUSTRY

lead

University Hospital, Ghent

OTHER

NCT05313984 - OptiLUTS Part C: the Development of a Symptom Assessment Tool in Sacral Neuromodulation. | Biotech Hunter | Biotech Hunter